These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The Mitroflow pericardial valve: clinical performance to 10 years.
    Author: Mazzucotelli JP, Bertrand PC, Loisance DY.
    Journal: J Heart Valve Dis; 1995 Jul; 4(4):407-13. PubMed ID: 7582152.
    Abstract:
    From 1983 to 1992, 366 patients received 407 Mitroflow pericardial bioprostheses at our institution. Mean age was 62 +/- 14 years (range: 15-86 years). There were 229 isolated aortic valve replacements (AVR), 96 isolated mitral valve replacements (MVR), 39 double mitral and aortic valve replacements (DVR) and four tricuspid replacements. Mean follow up was 6 +/- 2.33 years ranging from 1.67 to 10.9 years. Total follow up was 1791 patient-years. Overall survival was 77.2 +/- 2.2% at five and 56.2 +/- 6.4% at 10 years. It was 74 +/- 3% and 56.2 +/- 5.3% after AVR, 78.3 +/- 4.4% and 55.7 +/- 8.8% after MVR, 81 +/- 6.4% and 36.6 +/- 16.5% after DVR at five and 10 years, respectively. Freedom from structural valve deterioration (SVD) was 95 +/- 1.2% and 36.7 +/- 8.1% at five and 10 years for all valves, 96.9 +/- 1.3% and 39.2 +/- 9.8% for AVR, 91.7 +/- 3.2% and 36.4 +/- 10% for MVR. There was no difference in freedom from SVD between AVR and MVR. The freedom from SVD in patients older than 70 years of age was 100% and 93.9 +/- 5.8% at five and 10 years, respectively. Freedom from reoperation was 94.7 +/- 1.37% and 28.36 +/- 7.5% at five and 10 years for all valves, 96.2 +/- 1.5% and 38.6 +/- 9.7% for AVR, 91.7 +/- 3.2% and 36.4 +/- 10% for MVR. The denaturation process did not lead to acute hemodynamic deterioration. Pathologic findings were cuspal tears (one or more) associated with structural tissue changes.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]